Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Oncoceutics Inc.
Headquarters: Hummelstown, PA, United States of America
Website: N/A
Year Founded: 2009
Status: Acquired
BioCentury | Mar 5, 2025
Deals
Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz
Building in oncology, Jazz obtains targeted glioma therapy under FDA review
BioCentury | May 16, 2022
Deals
May 16 Quick Takes: Agios again narrows focus
Plus Shionogi-F2G, Chimerix, Travere, Valneva and more
BioCentury | Nov 6, 2021
Deals
Nov. 5 Quick Takes: $103M raise to support bit.bio’s cell coding tech
Plus Alphabet launches digital biology venture, IO Biotech’s IPO, setbacks for Deciphera, Calithera and more
BioCentury | Jan 8, 2021
Finance
Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more
Carlyle leads Abbisko’s $123M series DShanghai-based oncology company Abbisko Therapeutics Co. Ltd. raised $123 million in a series D round led by the Carlyle Group. The company
BioCentury | Apr 11, 2020
Management Tracks
Harpal Kumar named president of Grail Europe; plus Notable, Oncoceutics, ReAlta, Parker Institute
BioCentury | Apr 10, 2020
Management Tracks
Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more
BioCentury | May 31, 2019
Translation in Brief
New target for Oncoceutics' GPCR-targeting compounds
Oncoceutics' compounds increase mitochondrial protease activity to kill cancer
BioCentury | Jun 2, 2018
Product Development
Breaking from the herd
New advances in PD-1 combinations, sarcoma treatments and nucleotides at ASCO
BioCentury | Jan 25, 2018
Translation in Brief
Melanoma vs. melanoma
PEDF-presenting exosomes may be able to prevent metastasis of melanoma
Items per page:
1 - 10 of 22